Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03707457
Title Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

glioblastoma

gliosarcoma

Therapies

Ipilimumab + Nivolumab

MK-4166 + Nivolumab

Epacadostat + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.